Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular accumulation of amyloid deposits and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau proteins. Brainderived neurotrophic factor (BDNF) is a neurotrophic factor playing a critical role in hippocampal synaptic plasticity and memory and whose levels have been shown reduced in AD brains. While recent data support a pivotal role of β-amyloid peptides towards BDNF decrease, whether Tau pathology impacts on BDNF expression remains unknown so far. In the present study, we have evaluated this relationship using quantitative PCR, Western blot and ELISA in the THY-Tau22 transgenic strain, known to display a progressive development of both hippocampal AD-like Tau pathology and memory impairments. We observed that Tau pathology was not associated with down-regulation of BDNF at the protein and mRNA levels in this model, suggesting that the alteration of BDNF homeostasis observed in AD patients’ brains might rather be ascribed to amyloid pathology.
Keywords: Alzheimer’s disease, BDNF, neurotrophins, tau, tauopathies, transgenic models, Protein Expression, ELISA analysis, synaptic plasticity, homeostasis
Current Alzheimer Research
Title:Hippocampal BDNF Expression in a Tau Transgenic Mouse Model
Volume: 9 Issue: 4
Author(s): Sylvie Burnouf, Karim Belarbi, Laetitia Troquier, Maxime Derisbourg, Dominique Demeyer, Antoine Leboucher and Cyril Laurent, Malika Hamdane, Luc Buee, David Blum
Affiliation:
Keywords: Alzheimer’s disease, BDNF, neurotrophins, tau, tauopathies, transgenic models, Protein Expression, ELISA analysis, synaptic plasticity, homeostasis
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular accumulation of amyloid deposits and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau proteins. Brainderived neurotrophic factor (BDNF) is a neurotrophic factor playing a critical role in hippocampal synaptic plasticity and memory and whose levels have been shown reduced in AD brains. While recent data support a pivotal role of β-amyloid peptides towards BDNF decrease, whether Tau pathology impacts on BDNF expression remains unknown so far. In the present study, we have evaluated this relationship using quantitative PCR, Western blot and ELISA in the THY-Tau22 transgenic strain, known to display a progressive development of both hippocampal AD-like Tau pathology and memory impairments. We observed that Tau pathology was not associated with down-regulation of BDNF at the protein and mRNA levels in this model, suggesting that the alteration of BDNF homeostasis observed in AD patients’ brains might rather be ascribed to amyloid pathology.
Export Options
About this article
Cite this article as:
Sylvie Burnouf, Karim Belarbi, Laetitia Troquier, Maxime Derisbourg, Dominique Demeyer, Antoine Leboucher and Cyril Laurent, Malika Hamdane, Luc Buee, David Blum , Hippocampal BDNF Expression in a Tau Transgenic Mouse Model, Current Alzheimer Research 2012; 9 (4) . https://dx.doi.org/10.2174/156720512800492468
DOI https://dx.doi.org/10.2174/156720512800492468 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Saponins in Tumor Therapy
Mini-Reviews in Medicinal Chemistry Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Alzheimers Disease and Non-Steroidal Anti-Inflammatory Drugs: Old Therapeutic Tools with Novel Mechanisms of Action?
Current Medicinal Chemistry - Central Nervous System Agents Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Dynamical Behaviors of the Transcriptional Network Including REST and miR-21 in Embryonic Stem Cells
Current Bioinformatics Normal Cytochrome c Oxidase Activity in Prion Protein Gene-Deficient Mice
Protein & Peptide Letters Amyloid – Membrane Interactions: Experimental Approaches and Techniques
Current Protein & Peptide Science SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design